Beijing-based Shouyao Holdings (Beijing) Co., Ltd (SHA: 688197) has announced a strategic adjustment regarding its drug candidate SY-1530. The company has decided to proactively terminate the clinical development of the BTK inhibitor as a monotherapy for recurrent/refractory mantle cell lymphoma (MCL) and other B-cell derived non-Hodgkin lymphoma (B-NHL). Despite this, the development of SY-1530 for other indications remains under consideration.
SY-1530: A Next-Generation BTK Inhibitor in Phase II Studies
SY-1530 is an in-house developed, highly selective, irreversible next-generation BTK kinase inhibitor currently undergoing Phase II studies for recurrent/refractory B-NHL. Globally, multiple BTK inhibitors have been approved for marketing, with indications including chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), marginal zone lymphoma (MZL), and Waldenström’s macroglobulinemia (WM). In China, BTK inhibitors such as Imbruvica (ibrutinib), Brukinsa (zanubrutinib), orelabrutinib, Calquence (acalabrutinib), and Jaypirca (pirtobrutinib) are commercially available, with the first two included in the National Reimbursement Drug List (NRDL). The competitive landscape in the BTK inhibitor market influenced Shouyao’s strategic decision.- Flcube.com
